Dave Icke

The Story

Most CEOs in healthcare arrive from healthcare. Dave Icke arrived from semiconductors. Before he ever thought about patients, his job was making sure microchips were flawless - and at KLA he grew that inspection business from $50 million to $700 million in revenue. The product was precision. The customer was a fab. Nobody was sick.

That detour matters, because it is the through-line of everything he has done since. Icke treats the body the way he once treated silicon: as a system you can measure, instrument, and improve if you are stubborn enough about the data. He runs Medisafe today, the medication engagement platform used by more than ten million patients, and his entire pitch is an engineer's pitch. A pill only works if it gets taken. So build the system that makes taking it the easy thing to do.

He took the top job at Medisafe in June 2025, stepping in for co-founder Omri Shor, who had spent thirteen years building the company after his diabetic father accidentally double-dosed on insulin. That origin story is intensely human. Icke's job is to make it scale - to push medication engagement across the global pharmaceutical ecosystem without losing the thing that made a worried son build an app in the first place.

Read his resume backwards and you get a map of how digital health actually grew up. At Humana he was VP of Digital Health Product, leading the teams that wired together telehealth and remote monitoring back when "connected care" still needed air quotes. Before that he launched Becton Dickinson's digital health business from nothing, aimed squarely at the unglamorous grind of chronic disease self-management. And before that he was the founding CEO of mc10, a company putting flexible biosensors directly on skin years ahead of the wearables boom - the kind of bet that looks obvious only in hindsight. Medidata eventually bought it.

Then there is ieso. In January 2023 he became Executive Chair of the British digital-health company teaching machines to deliver evidence-based mental health therapy. "I admire ieso for its commitment to making evidence-based mental healthcare more effective and accessible," he said at the time. It is a tell. Across wearables, chronic care, mental health and now medication adherence, the constant is not the disease. It is the insistence that the intervention be measurable and the access be wider.

His training reads like a deliberate two-part argument. A Stanford degree in chemical engineering gave him the builder. A Harvard MBA gave him the operator. He has used both: P&L roles at Teradyne with annual sales responsibility up to $500 million taught him how to run a number, and a string of digital-health seats taught him what the number is for. CEO Today Magazine put him on its Healthcare Awards list in 2023, which is the industry's polite way of saying people noticed.

What is genuinely unusual about Icke is how many seats he has occupied. Founder. Business-line launcher inside a giant. Product VP. Executive chair. Now chief executive. Most people in this world pick a lane - they are operators or they are founders, they do hardware or they do software. He keeps refusing the choice, and the refusal is the point. Medisafe sits exactly where hardware-minded rigor meets software-scale distribution meets a drug that has to be swallowed on schedule. It is, in other words, the job his whole career has been auditioning for.

The work ahead is not subtle. Pharma is under pricing pressure, patients abandon prescriptions at the first refill, and "adherence" remains one of the largest and least-solved problems in medicine. Icke's answer is the one he has been giving since the microchip days: stop treating the patient as the variable you can't control, and start building the system around them. Whether that scales to the next ten million is the open question. He has spent twenty years arguing it can.